Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Conference News NY Valves 2025

Prompt TAVI Benefits Asymptomatic AS Patients Regardless of Guideline Indication

Todd Neale

June 27, 2025

News Conference News NY Valves 2025

Long-term Survival Better With TAVI Explant vs Redo: Medicare Data

Yael L. Maxwell

June 26, 2025

Presentation NY Valves 2025

AVR in Asymptomatic Severe Aortic Stenosis: The EARLY TAVR Trial and Beyond

Presenter: Brian R. Lindman

June 26, 2025

Presentation NY Valves 2025

Feasibility of Valve-in-Valve After TAVR: A Comparative Study of Sapien 3 vs. Surgical AVR

Presenter: Tej Sheth

June 26, 2025

News Conference News NY Valves 2025

Alerts to Physicians Close Gaps in AS Management Between Women, Men

Todd Neale

June 25, 2025

Presentation NY Valves 2025

Late Health Status Outcomes with Patient-Prosthesis Mismatch After AVR in the PARTNER Trials

Presenter: Yasser M. Sammour

June 25, 2025

Presentation NY Valves 2025

Guideline Directed Indications and Consequences of Delayed AVR in Patients With Asymptomatic, Severe Aortic Stenosis: Results From the EARLY TAVR Trial

Presenter: Allan Schwartz

June 25, 2025

News Conference News NY Valves 2024

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

Todd Neale

June 14, 2024

News Conference News NY Valves 2024

National Data Point to Soaring TAVI Rates in Patients Under 65

Michael O'Riordan

June 14, 2024

Presentation NY Valves 2024

UPDATES: Pre-emptive AVR Clinical Trials for Moderate and Severe AS

Presenter: Philippe Pibarot

June 07, 2024

Presentation NY Valves 2024

Pre-emptive AVR for Moderate AS and Asymptomatic Severe AS: A Summary of Upcoming Trials

Presenter: Nicolas M. Van Mieghem

June 06, 2024

Presentation NY Valves 2024

Why Favor Redo SAVR After a Failed Bioprosthetic AVR?

Presenter: Tsuyoshi Kaneko

June 06, 2024

Presentation NY Valves 2024

Medical Management Post AVR

Presenter: Javed Butler

June 05, 2024

Presentation NY Valves 2024

Requirements for GDMT in UPSTREAM AVR Clinical Trials in (1) Preserved EF or (2) Reduced EF Patients

Presenter: Parag Goyal

June 05, 2024

Advertisement

Prompt TAVI Benefits Asymptomatic AS Patients Regardless of Guideline Indication

Long-term Survival Better With TAVI Explant vs Redo: Medicare Data

AVR in Asymptomatic Severe Aortic Stenosis: The EARLY TAVR Trial and Beyond

Feasibility of Valve-in-Valve After TAVR: A Comparative Study of Sapien 3 vs. Surgical AVR

Alerts to Physicians Close Gaps in AS Management Between Women, Men

Late Health Status Outcomes with Patient-Prosthesis Mismatch After AVR in the PARTNER Trials

Guideline Directed Indications and Consequences of Delayed AVR in Patients With Asymptomatic, Severe Aortic Stenosis: Results From the EARLY TAVR Trial

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

National Data Point to Soaring TAVI Rates in Patients Under 65

UPDATES: Pre-emptive AVR Clinical Trials for Moderate and Severe AS

Pre-emptive AVR for Moderate AS and Asymptomatic Severe AS: A Summary of Upcoming Trials

Why Favor Redo SAVR After a Failed Bioprosthetic AVR?

Medical Management Post AVR

Requirements for GDMT in UPSTREAM AVR Clinical Trials in (1) Preserved EF or (2) Reduced EF Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content